TIMI 10A

OBJECTIVE: To evaluate the pharmacokinetics, safety and efficacy of several doses of TNK-tPA among patients presenting with acute ST elevation myocardial infarction.

View/Download
_______________________________________________________________________________

1. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Cannon CP, McCabe CH, Gibson CM, et al. Circulation 1997;95:351-6.
   | Abstract | Request Reprints |
   

2. Relationship between timing of vessel opening after thrombolysis and flow at 90 minutes.Rizzo MJ, Cannon CP, McLean C, Martin NE, Mukesh G, Marble SJ, Dodge T, Gibson M, for the TIMI 10A Investigators. Circulation 1996;94[Suppl. I]:I-440.
   | Request Reprints |
   
   
3. Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Tanasijevic MJ, Cannon CP, Wybenga DR, et al. Am Heart J 1997;134:622-30.
   | Abstract | Request Reprints |
   
   
4. Predictors of slowed non-culprit blood flow post thrombolysis. McLean C, Rizzo M, Ryan K, McCabe C, Cannon CP, Gibson M, Braunwald E, for the TIMI 10A Investigators. J Am Coll Cardiol 1997;29 (Suppl. A):131A.
   | Request Reprints |
   
   
5. Persistent myoglobin elevation is associated with slower flow in patent culprit arteries following successful thrombolysis. Rizzo M, Dotani I, McLean C, Ryan K, McCabe CH, Tanasijevic M, Cannon C, Gibson M, Braunwald E, for the TIMI 10A Trialists. J Am Coll Cardiol 1997;29 (Suppl. A):132A.
   | Request Reprints |
   
   
6. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. Modi NB, Fox NL, Clow FW, et al. J Clin Pharmacol 2000;40:508-15.
   | Request Reprints |